
|Videos|August 13, 2015
METGastric Study Results
Author(s)Manish A. Shah, MD
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
Advertisement
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
While the MET pathway is significant in predicting gastrointestinal (GI) cancers, it is a redundant pathway, said Shah. There are many ways to activate the pathways and increase pro-survival signaling, such as through EGFR, HER2 or IGFR, according to Shah.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































